SaaS for senior care operators to schedule companion robots, track resident outcomes, and generate payer documentation.

1. Tombot's Fall 2026 first shipments will deliver thousands of units to facilities with no operational infrastructure in place, creating a deployment-documentation gap on a known calendar date.
2. 23,000 pre-orders confirm senior care buyers have committed capital before any workflow tooling exists, creating a first-mover window before robots physically arrive.
3. Healthcare operator investors (Lutheran Foundation for Long Term Living, Florida Community Health Network) validate that care delivery organizations are already seeking deployment infrastructure, not just hardware.
4. CMS expansion of value-based care contracts into long-term care is accelerating demand for structured non-pharmacological intervention documentation that companion robot logs can supply.
5. The 300M+ dementia population at scale will force CMS to develop companion-robot reimbursement criteria; the platform that owns outcome data will define the measurement standard before payers have written the rules.

Catalyst. Tombot's Fall 2026 commercial launch will flood memory care facilities with companion robots that have no operational layer, creating a simultaneous thousands-of-unit deployment gap with no incumbent software vendor to fill it.

A SaaS platform giving senior care operators a companion robot fleet management dashboard covering resident-robot scheduling, interaction session logging, engagement score tracking, and automated clinical documentation exports compatible with EHR systems. The system surfaces outcome metrics — agitation reduction, sleep improvement, social engagement frequency — in formats required for value-based care audits and future payer submissions. Setup takes under one day per facility via a lightweight app paired to nursing staff tablets, with no on-site hardware integration required beyond existing Wi-Fi and the robot manufacturer API.

What's different. Unlike generic activity tracking modules bundled into EHRs, this platform is purpose-built around robot interaction data — capturing session-level behavioral signals (engagement duration, agitation events, vocalization frequency) that no EHR vendor currently collects. The earliest integration partnerships with Tombot and PARO create a data network effect: the more facilities use the platform, the richer the outcome benchmarking dataset becomes, and no new entrant can replicate that without years of deployment. The platform becomes the de facto reimbursement documentation standard before payers have written the criteria.

Jobs to be done

flowchart LR
  PO[Robot Purchase Order] --> Onboard[Facility Onboarding\n<1 day]
  Onboard --> Schedule[Resident-Robot\nScheduler]
  Schedule --> Session[Interaction\nSession Logger]
  Session --> Analytics[Behavioral\nOutcome Analytics]
  Analytics --> EHR[EHR Export\nPointClickCare / MatrixCare]
  Analytics --> VBC[Value-Based Care\nAudit Reports]
  EHR --> ROI[CFO ROI\nJustification]
  VBC --> ROI

Executive takeaways

• Tombot's planned 2026 launch turns companion robotics from a theoretical category into an operational deployment problem: the company says it already has more than 23,000 pre-order and waitlist customers, while its investor materials cite 20,000+ reservations from 116 countries.[31][33]
• The compliance angle is real, but it is not robot reimbursement yet: CMS GUIDE funds dementia care navigation and respite, and revised nursing-home survey guidance keeps pushing providers toward documented non-pharmacologic care and psychotropic stewardship.[1][2][5][75]
• The strongest incumbents are split between hardware vendors and EHR systems. That leaves room for a neutral operations layer, but only if it integrates cleanly and does not over-claim clinical efficacy.[23][24][25][28][36][39][40][41][65]
• Public and quasi-public programs already show willingness to fund companion technology when outcomes are legible: New York's ElliQ program reached 834 participants with 94% reporting less loneliness and 97% better overall wellness, and Washington Medicaid coverage gives a concrete reimbursement-adjacent precedent.[46][48][50][53][54]

Market definition

The relevant market is not elder-care robots in the abstract; it is workflow and documentation software for companion-robot programs inside U.S. senior care operators. The product sits between device adoption, non-pharmacologic dementia care, and EHR interoperability: it schedules scarce robot sessions, captures resident-level intervention logs, and turns them into auditable care documentation for assisted living and nursing-home teams.[1][2][5][23][28][36][40]

Customer and buyer

The operational user is the memory-care or wellness staff member assigning robot sessions, but the economic buyer is usually a Director of Nursing, memory-care director, clinical informatics leader, or regional operator who already owns EHR workflows and survey risk. The beachhead is plausible because assisted living alone counts roughly 41,465 communities and nearly 1.4 million licensed beds, while U.S. nursing homes add another 14,700 facilities; assisted-living dementia prevalence is already high enough that workflow standardization matters even before robot-specific reimbursement exists.[6][11][74]

Buying triggers

• Robot shipment confirmation or waitlist conversion forces the operator to answer who will schedule sessions, document usage, and defend ROI to leadership. [31][33]
• Surveyor and clinical leadership pressure to show non-pharmacologic interventions before or alongside psychotropic use makes structured session logging more valuable. [2][5][10][75]
• Existing technology roadmaps already prioritize EHR, staffing, point-of-care documentation, and analytics, so a robot-ops tool can ride an established IT buying motion instead of inventing one. [13][14][23]

Willingness to pay

Budget room is plausible when framed against existing care-tech and care-delivery spend. ElliQ sells at $39-$59 per month direct-to-consumer, Joy for All pets sit around $160-$180 one-time, PointClickCare's USCDI Connector pricing is $65 per app per facility per month, and senior care itself is expensive—CareScout's 2025 national medians are $6,200 per month for assisted living and $9,581 for a semi-private nursing-home room. A few hundred dollars per facility per month is therefore believable if the software reduces documentation time or improves utilization, but buyers will still demand proof before broad rollout. [15][23][41][57][58]

Category dynamics

Growth signal 13.7% CAGR

Validation signals

• Tombot says it has more than 23,000 pre-order and waitlist customers ahead of first customer launch.
• NYSOFA's third-year ElliQ program reached 834 older adults and reported 94% less loneliness and 97% better overall wellness.
• Washington Medicaid coverage for ElliQ shows that a public payer can fund companion-tech deployment when the program looks like supportive care rather than gadget retail.
• Senior living providers already rank analytics, EHR, point-of-care documentation, and wander-management among top near-term technology investments.

Regulatory & technical constraints

• Long-term care survey guidance now puts psychotropic and chemical-restraint oversight into a tighter documentation framework, so the product must preserve resident-specific evidence of non-pharmacologic interventions and outcomes.
• Any claims about reducing agitation, loneliness, or clinical symptoms need substantiation and careful marketing discipline under FTC health-claims rules.
• EHR write-back is feasible but not free: PointClickCare prices FHIR access per app per facility and incumbent partner ecosystems can gate deployment speed.
• Robot hardware data is still fragmented across waitlists, memberships, and OEM-specific programs rather than a standard clinical event schema.

The category is fragmented. Tombot is trying to create a scaled dementia-companion hardware category; PARO has the deepest clinical or medical-device positioning; ElliQ has public-program traction and a subscription model; PointClickCare and MatrixCare own the longitudinal record and partner channels; and low-cost robotic pets absorb price-sensitive demand. None of these players appears to offer a neutral, multi-vendor operations and payer-documentation layer for facility fleets.[23][24][25][28][36][39][40][41][57]

Why incumbents do not win by default

• Companion robot OEMs. OEMs want to sell and support their own device, not become the cross-vendor workflow layer for every session, note, and payer artifact in a facility.
• EHR platforms. PointClickCare and MatrixCare have the system-of-record advantage and partner ecosystems, but their public materials emphasize interoperability and marketplace extensibility rather than robot-specific session telemetry or intervention benchmarking.
• Consumer robotic pets. Low-cost robotic pets can satisfy companionship use cases at $160-$180, but they do not generate structured outcomes, staffing workflows, or EHR-connected documentation.
• Public aging programs. Programs like NYSOFA and Washington Medicaid prove budget and demand, but they still need operational partners that can onboard devices, train staff, and produce consistent evidence at provider level.
• Clinical evidence gatekeepers. PARO's device-style evidence and FDA or NLM listing show that trust accumulates around measurable therapeutic claims; a software layer must support that evidence process without making unsupported claims itself.

Senior care facilities are about to receive thousands of companion robots (Tombot Jennie, PARO, ElliQ) with no operational infrastructure to schedule sessions, track resident outcomes, or generate the clinical documentation that value-based care audits and board ROI reviews demand. Care Robot Ops Platform is a SaaS layer that sits between robot hardware and the EHR — scheduling resident-robot sessions, capturing interaction telemetry, and exporting structured outcome reports into PointClickCare and MatrixCare. The primary buying trigger is Tombot's Fall 2026 commercial shipment of Jennie units to 23,000+ pre-order customers; the Director of Nursing receives the robot and immediately faces CFO scrutiny and potential CMS surveyor questions about non-pharmacologic intervention documentation. The beachhead is memory care units at 100-300-bed U.S. assisted living facilities with active Tombot purchase orders, a segment where over 42% of residents already have dementia and where the compliance pressure is highest. The company wins by being the first to own robot session data across multiple hardware vendors and embedding EHR write-back before incumbents can respond; a growing cross-facility outcome benchmark dataset then becomes a durable moat that no late entrant can replicate without years of deployed usage. The initial SaaS price of $500-800 per facility per month is a rounding error against the $3,000-5,000 robot capital cost it justifies and the 2-4 nursing hours per week it saves; the long-term path is to become the reimbursement documentation standard for all non-pharmacological senior care interventions. One material gap in the current evidence base is the exact share of Tombot pre-orders belonging to facilities in the 100-300-bed assisted living segment; the SAM and beachhead headcount must be validated in the first 90 days of customer discovery.

Problem

• Senior care facilities receiving companion robots in Fall 2026 have no scheduling tool to assign resident-robot sessions, track utilization, or prevent robots from sitting unused.
• Directors of Nursing face immediate CFO ROI review after robot delivery with only paper activity logs and anecdotal staff notes — no structured outcome data to defend the capital spend.
• Value-based care contracts and tightening CMS survey guidance (QSO-25-07, National Partnership) require documented non-pharmacologic intervention records; manual EHR free-text notes fail this standard.
• No neutral software layer exists to normalize session data across robot vendors (Tombot, PARO, ElliQ) into a single facility-grade documentation workflow.
• Robot OEM dashboards, if they exist, are device-specific and do not write back to the resident record in PointClickCare or MatrixCare where surveyors and care teams actually look.

Solution

• SaaS fleet management dashboard: resident-robot scheduling, one-tap session logging, engagement scoring, and agitation/sleep/social engagement outcome tracking across robot types.
• Automated clinical documentation export into PointClickCare and MatrixCare via SMART on FHIR and USCDI Connector; day-1 fallback via CSV import for facilities where EHR API access is pending.
• CFO ROI and surveyor-ready outcome reports generated automatically after each session cycle, showing agitation reduction, nursing hours saved, and robot utilization vs. capital cost.
• Setup under one day per facility via nursing staff tablets and Wi-Fi — no on-site hardware, no IT project required.
• Cross-facility outcome benchmark reports (anonymized peer cohort) delivered monthly, creating an ongoing evidence asset for payer negotiations and CMS compliance.

Why we win

• First-mover timing: Tombot's Fall 2026 commercial launch is a known calendar event creating simultaneous demand across thousands of facilities with no incumbent software vendor positioned to respond.
• Data network effect: normalized session telemetry across robot vendors and facilities compounds into the only cross-facility companion-robot outcome benchmark dataset — unreplicable without years of deployment.
• EHR integration as a moat: embedding PointClickCare and MatrixCare write-back before EHR vendors build natively makes the platform the structured data supplier, positioning partnership over displacement.
• Regulatory tailwind ownership: by building documentation templates aligned to CMS surveyor guidance now, the platform can shape what payers define as a reimbursable outcome metric before criteria exist.
• Channel leverage: operator investors (Lutheran Foundation for Long Term Living, Florida Community Health Network) inside Tombot's own cap table are natural design partners and channel references.
• Narrow, defensible scope: EHR vendors and OEMs are not positioned to build a neutral multi-vendor robot operations layer; the startup is not competing with them but feeding structured data into their systems.

Milestones

flowchart LR
  PreOrder[Tombot Pre-Order\nWaitlist Access] --> Outreach[Direct DON\nOutreach]
  Outreach --> Pilot[Paid Pilot\n30-day onboarding]
  Pilot --> MVP[Session Scheduler\n+ Outcome Logger]
  MVP --> EHR[PointClickCare\nFHIR Write-Back]
  EHR --> Proof[CFO ROI Report\n+ Audit Pass]
  Proof --> Expand[Multi-Facility\nEnterprise Contract]
  MVP --> Benchmark[Cross-Facility\nOutcome Benchmark]
  Benchmark --> Expand
  Expand --> DataMoat[Payer Documentation\nStandard Ownership]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 500 U.S. assisted living facilities in the 100-300 bed segment receive Tombot Jennie units in the 12 months following Fall 2026 commercial launch — otherwise the deployment wave is too small for the beachhead.
• Directors of Nursing at facilities with active robot purchase orders will pay $500-800/month for scheduling and documentation software before CMS companion-robot reimbursement exists, based on operational ROI (nursing hours saved, survey readiness) alone.
• Tombot and at least one other OEM (PARO or ElliQ) will grant API telemetry access to a neutral third-party operations platform rather than building their own fleet management SaaS.
• PointClickCare SMART on FHIR integration can be deployed at a new facility in under one week without a custom IT project, making EHR write-back a competitive entry barrier rather than a deployment bottleneck.
• The cross-facility outcome benchmark dataset becomes a meaningful retention and expansion driver: facilities with 3+ months of normalized session data show Net Revenue Retention above 110% and resist churning to a later OEM-native tool.

Open diligence questions

• How many of Tombot's 23,000 pre-orders are from 100-300 bed U.S. assisted living facilities specifically, and what is the confirmed delivery timeline for this segment?
• Will Tombot share customer identity and shipment confirmation timing with a preferred SaaS partner, or must the startup find pre-order customers through independent outreach?
• What telemetry does Tombot's current API expose — session start/end, behavioral signals, battery/status — and on what timeline will it be available to third-party developers?
• Have any Directors of Nursing at facilities with companion robot purchase orders already attempted to solve the documentation problem, and what did they try?
• What is PointClickCare's current process and timeline for certifying a new USCDI Connector app, and are there revenue-share terms that affect the unit economics?
• Would Lutheran Foundation for Long Term Living or Florida Community Health Network pilot the product at their own facilities, and on what terms?

Model sanity

• Revenue engine. Base-case revenue is driven by a 20 to 50 to 130 facility ramp at roughly $8.4K blended ARR, with most wins coming from shipment-triggered single-site sales before multi-site expansion matters.
• Must go right. The model depends on PointClickCare and OEM integrations staying lightweight enough that a ~$5.8K CAC still pays back in about 11 months on a low-ACV subscription.
• Model breaks if. If ARPU compresses toward $7.2K and close cycles slip by a quarter, the downside case pushes cash slightly negative before Y3 ends.
• Next-round proof. Hitting 50 paying facilities, one 5+ site operator contract, and retention proof by Q4Y2 is the operating milestone that best supports the next financing.

Scenarios

Sensitivity

flowchart LR
  Shipments[Robot shipment confirmations] --> Pilots[Facility pilots]
  Pilots --> Facilities[Paying facilities]
  Facilities --> Revenue[Subscription revenue]
  Revenue --> GrossProfit[74% gross profit]
  GrossProfit --> Cash[Runway to 50-facility proof]

Flags: The base case already assumes the company reaches 20 facilities in Year 1 and 50 by Q4Y2, so any delay in Tombot shipments or PointClickCare deployment would pressure the entire model quickly. · Revenue per FTE is still light by Y3, which means the venture case depends on later enterprise dashboards, benchmark data, or therapy-module expansion lifting ARPU beyond the base-case subscription alone. · Cash stays positive on a $2.3M pre-seed only because hiring remains unusually lean; pulling forward a second seller or a full regulatory team before operator proof would likely force an earlier round.

• Robot Manufacturer Vertical Integration. Tombot or PARO could build their own operational software layer and bundle it with hardware, eliminating the need for a third-party platform. Mitigation: Pursue co-marketing and preferred integration partnerships with robot manufacturers before Fall 2026 launch, framing the platform as complementary to hardware and expanding the robot TAM rather than competing with it.
• CMS Reimbursement Timeline Uncertainty. If CMS takes 3-5 years to formalize companion robot reimbursement criteria, the ROI case remains soft and facilities deprioritize documentation tooling investment. Mitigation: Build immediate ROI around nursing labor savings and value-based care audit compliance — not CMS reimbursement — so the product pays for itself before the reimbursement win materializes.
• EHR Vendor Competition. PointClickCare or MatrixCare could add companion robot activity tracking to their existing platforms, leveraging incumbent facility relationships to crowd out a standalone tool. Mitigation: Achieve EHR integration status before EHR vendors build natively; position as a robot outcome data supplier feeding structured signals into the EHR rather than a competing workflow layer, making partnership more attractive than displacement.